ArticleOpen forum infectious diseases2017
Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- No improvement in clinical outcomes: a propensity score analysis of inappropriate carbapenem use in children with susceptibleFrontiers in cellular and infection microbiology · 2026Article
- A NovelAntibiotics (Basel, Switzerland) · 2024Article
- Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study.The Journal of antimicrobial chemotherapy · 2024Observational
- Effectiveness of empiric carbapenem versus non-carbapenem therapy for extended-spectrum β-lactamase producing Enterobacterales infections in non-intensive care unit patients: a real-world investigation in a hospital with high-prevalence of extended-spectrum β-lactamase producing Enterobacterales.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Current and Emerging Treatment Options for Multidrug ResistantAntibiotics (Basel, Switzerland) · 2022Review
- Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.The Journal of antimicrobial chemotherapy · 2022Article
- Carbapenem-ResistantInfection and drug resistance · 2022Article
- A Focus on Evaluating Major Study Limitations in Order to Apply Clinical Trials to Patient Care: Implications for the Healthcare Team.Hospital pharmacy · 2021Article
- Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection.JAC-antimicrobial resistance · 2021Review
- The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum.Infection & chemotherapy · 2021Article
- Article
- Molecular Mechanisms, Epidemiology, and Clinical Importance of β-Lactam Resistance inInternational journal of molecular sciences · 2020Review
- Point-counterpoint: The MERINO trial and what it should imply for future treatment of ESBL bacteremia.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2019Article
- Review
- Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-ProducingAntimicrobial agents and chemotherapy · 2019Article
- Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producingAntimicrobial resistance and infection control · 2019Article
- Derivation and validation of a simple score to predict the presence of bacteria requiring carbapenem treatment in ICU-acquired bloodstream infection and pneumonia: CarbaSCORE.Antimicrobial resistance and infection control · 2019Article
- Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?Intensive care medicine · 2018Article
- Clinical Outcomes of Extended-Spectrum Beta-Lactamase-ProducingThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenems are widely used for the management of bloodstream infections (BSIs) caused by extended-spectrum β-lactamase-producing
methodsWe searched the PubMed and Scopus databases (last search date was on June 1, 2016) looking for studies that reported mortality in adult patients with ESBL-PE BSIs that were treated with carbapenems or β-lactam/β-lactamase inhibitors (BL/BLIs).
resultsFourteen studies reported mortality data in adult patients with ESBL-PE BSI that were treated with carbapenems or BL/BLIs. Among them, 13 studies reported extractable data on empiric therapy, with no statistically significant difference in mortality of patients with ESBL-PE BSI that were treated empirically with carbapenems (22.1%; 121 of 547), compared with those that received empiric BL/BLIs (20.5%; 109 of 531; relative risk [RR], 1.05; 95% confidence interval [CI], 0.83-1.37; I
conclusionsThese data do not support the wide use of carbapenems as empiric therapy, and BL/BLIs might be effective agents for initial/empiric therapy for patients with BSI caused by likely ESBL-PE, and especially ESBL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.